Business Context and Reporting Period
Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company developing Multi-Antigen Recognizing (MAR)-T cell therapies for hematological malignancies and solid tumors. This Form 10-Q covers the quarterly period ended June 30, 2025. The Company is classified as a non-accelerated filer and a smaller reporting company. As of August 4, 2025, there were 12,938,910 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | As of June 30, 2025 |
|---|---|---|---|
| Total Revenues | $861,184 | $1,210,288 | N/A |
| Net Loss | $(4,015,564) | $(8,461,748) | N/A |
| Net Loss Per Share (Basic & Diluted) | $(0.29) | $(0.67) | N/A |
| Operating Expenses | $5,122,217 | $10,079,994 | N/A |
| Cash, Cash Equivalents, and Restricted Cash | N/A | N/A | $11,814,946 |
| Working Capital | N/A | N/A | $10,490,393 |
| Total Liabilities | N/A | N/A | $4,277,477 |
Note: Revenues consist entirely of grant income. The Company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 26% in the three months ended June 30, 2025, compared to the prior year period, and 50% for the six-month period. This is primarily due to the recognition of grant income timing.
- Increased Operating Expenses: Operating expenses rose 47% year-over-year for the quarter and 39% for the six-month period. Research and Development (R&D) expenses increased 79% for the quarter and 49% for the six months, driven by higher clinical trial and consulting costs.
- Unusual Item: The six-month period included a $453,135 loss on the early termination of a vendor agreement with Cell Ready, LLC, a related party. This charge was not present in the prior year period.
- Related Party Payables: Related party payables decreased from $1.71 million at year-end 2024 to $0.66 million at June 30, 2025, reflecting payments made to Baylor College of Medicine and Cell Ready.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management has raised substantial doubt regarding the Company's ability to continue as a going concern. Based on current cash balances and the recent ATM sale, the Company anticipates funding operations into the second quarter of 2026, assuming no additional grant funds are received.
- Recent Capital Raise: Between July 17 and 21, 2025 (subsequent to the period end), the Company sold 1,624,075 shares via its ATM Agreement for net proceeds of $4.5 million at an average price of $2.87 per share.
- Manufacturing Transition: The Company terminated its agreement with Cell Ready and entered into a new Statement of Work with Cellipont Bioservices in June 2025 to support cGMP manufacturing for the APOLLO study (MT-601).
- Grant Funding: The Company relies heavily on grants from CPRIT, NIH, and the FDA. While several grants are active, future funding is not guaranteed. Revenue sharing obligations exist for CPRIT grants upon commercialization.
- Executive Compensation: On August 8, 2025, the Board increased the CEO's annual base salary from $400,000 to $440,000.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $11.8 million cash balance against the projected burn rate to confirm the Q2 2026 liquidity timeline.
- Grant Receivables: Confirm the collectability of the ~$1.7 million in grant income receivables recorded on the balance sheet.
- Manufacturing Scalability: Assess the progress of the technology transfer to Cellipont Bioservices to ensure no delays in the pivotal APOLLO trial.
- Dilution Risk: Monitor the exercise of the 7.67 million outstanding warrants (including pre-funded warrants) and potential future equity issuances required to extend the runway beyond 2026.
- Related Party Transactions: Review the terms of the new manufacturing agreement and ongoing expenses related to Baylor College of Medicine to ensure arm's-length pricing.